Abstrakt

Przypisy

• 1. Ambros P.F., Ambros I.M., Brodeur G.M., Haber M., Khan J., NakagawaraA., Schleiermacher G., Speleman F., Spitz R., London W.B.,Cohn S.L., Pearson A.D., Maris J.M.: International consensus for neuroblastomamolecular diagnostics: report from the InternationalNeuroblastoma Risk Group (INRG) Biology Committee. Br. J. Cancer,2009; 100: 1471-1482
  Google Scholar
• 2. Bagatell R., Beck-Popovic M., London W.B., Zhang Y., PearsonA.D., Matthay K. K., Monclair T., Ambros P.F., Cohn S.: Significanceof MYCN amplification in international neuroblastoma staging systemstage 1 and 2 neuroblastoma: a report from the InternationalNeuroblastoma Risk Group database. J. Clin. Oncol., 2009; 27: 365-370
  Google Scholar
• 3. Bown N., Cotterill S., Lastowska M., O’Neill S., Pearson A.D., PlantazD., Meddeb M., Danglot G., Brinkschmidt C., Christiansen H.,Laureys G., Speleman F., Nicholson J., Bernheim A., Betts D.R., VandesompeleJ., Van Roy N.: Gain of chromosome arm 17q and adverseoutcome in patients with neuroblastoma. N. Engl. J. Med., 1999;340: 1954-1961
  Google Scholar
• 4. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V.,Castleberry R.P., De Bernardi B., Evans A.E., Favrot M., Hedborg F.,Kaneko M., Kemshead J., Lampert F., Lee R.E., Look A.T. i wsp.: Revisionsof the international criteria for neuroblastoma diagnosis, staging,and response to treatment. J. Clin. Oncol., 1993; 11: 1466-1477
  Google Scholar
• 5. Chen L., Malcolm A.J., Wood K.M., Cole M., Variend S., CullinaneC., Pearson A.D., Lunet J., Tweddle D.A.: p53 is nuclear and functionalin both undifferentiated and differentiated neuroblastoma. CellCycle, 2007; 6: 2685-2696
  Google Scholar
• 6. Cohn S.L., London W.B., Huang D., Katzenstein H.M., Salwen H.R.,Reinhart T., Madafiglio J., Marshall G.M., Norris M.D., Haber M.:MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol.,2000; 18: 3604-3613
  Google Scholar
• 7. Crist W., Kun L.: Common solid tumors of childhood. N. Engl. J.Med., 1991, 324: 461-471
  Google Scholar
• 8. Cui H., Hu B., Li T., Ma J., Alam G., Gunning W.T., Ding H.F.: Bmi-1is essentials for the tumorigenicity of neuroblastoma cells. Am. J.Pathol., 2007; 170: 1370-1378
  Google Scholar
• 9. Fasano C.A., Dimos J.T., Ivanova N.B., Lowry N., Lemischka I.R.,Temple S., Sarna S.: shRNA knockdown of Bmi-1 reveals a criticalrole for p21-Rb pathway in NSC self-renewal during development.Cell Stem Cell, 2007; 7: 87-99
  Google Scholar
• 10. Francis N.J., Kingston R.E.: Mechanisms of transcriptional memory.Nat. Rev. Mol. Cell. Biol., 2001; 2: 409-421
  Google Scholar
• 11. Frebourg T., Friend S.H.: Cancer risks from terminal p53 mutations.J. Clin. Incest., 1992; 90: 1637-1641 12 Fredlund E., Ringnér M., Maris J.M., Påhlman S.: High Myc pathwayactivity and low stage of neuronal differentiation associatewith poor outcome in neuroblastoma. Proc. Natl. Acad. Sci. USA,2008; 105: 14094-14099
  Google Scholar
• 12. to 18 months old with disseminated neuroblastoma: a PediatricOncology Group study. J. Clin. Oncol., 2005; 23: 6466-6473
  Google Scholar
• 13. Garrett M.: Neuroblastoma: biological insights intro a clinicalenigma. Cancer, 2003; 163: 245-253
  Google Scholar
• 14. George R.E., London W.B., Cohn S.L., Maris J.M., Kretschmar C.,Diller L., Brodeur G.M., Castleberry R.P., Look A.T.: Hyperdiploidyplus nonamplified MYCN confers a favorable prognosis in children
  Google Scholar
• 15. Gil J., Bernard D., Peters G.: Role of polycomb group proteins instem cell self-renewal and cancer. DNA Cell Biol., 2005; 24: 117-125
  Google Scholar
• 16. Hachitanda Y., Tsuneyoshi M.: Neuroblastoma with a distinctorganoid pattern: a clinicopathologic, immunohistochemical andultrastructural study. Human Pathol., 1994; 25: 67-72
  Google Scholar
• 17. Hang F., Sui L., Xin T.: Correlations of BMI-1 expression and telomeraseactivity in ovarian cancer tissues. Exp. Oncol., 2008; 30: 70-74
  Google Scholar
• 18. Hosoi G., Hara J, Okamura T, Osugi Y, Ishihara S, Fukuzawa M,Okada A, Okada S, Tawa A.: Low frequency of the p53 gene mutationsin neuroblastoma. Cancer, 1994; 73: 3087-3093
  Google Scholar
• 19. Jacobs J.J., van Lohuizen M.: Polycomb repression: from cellularmemory to cellular proliferation and cancer. Biochim. Biophys.Acta, 2002; 1602: 151-161
  Google Scholar
• 20. Jacobs, J.J., van Lohuizen, M.: Cellular memory of transcriptionalstates by polycomb-group proteins. Semin. Cell. Dev. Biol.,1999; 10: 227-235
  Google Scholar
• 21. Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,Gomer C.J., Triche T.J., Reynolds C.P.: Loss of p53 function confershigh level multidrug resistance in neuroblastoma cell lines. CancerRes., 2001; 61: 6185-6193
  Google Scholar
• 22. Kozakowski N., Seloiman A., Hammer J.: BMI-1 expression isinversely correlated with the grading of renal clear cell carcinoma.Pathol. Oncol. Res., 2008; 14: 9-13
  Google Scholar
• 23. Lassard J., Sauvageau G.: Bmi-1 determines the proliferative capacityof normal and leukaemic stem cells. Nature, 2003; 423: 255-260
  Google Scholar
• 24. Liu J., Song L., Hang X., Guo B., Feng Y., Li X., Liao W., Zeng M.,Huang K.: Bmi-1 expression predicts prognosis for patients withgastric carcinoma. J. Surg. Oncol., 2008; 97: 267-272
  Google Scholar
• 25. Majia M., Nawarro S., Pelplin A., Ruiz A., Pastel V, Lombard-BoschA.: Study of proliferation and apoptosis in neuroblastoma. their relationwiht rother prognostic factors. Arch. Med. Res., 2002; 33: 446-472
  Google Scholar
• 26. McLaughlin K.A., Rones M.S., Mercola M.: Notch regulates cellfate in the developing pronephros. Dev. Biol., 2000; 227: 567-580
  Google Scholar
• 27. Mihic-Probst D., Kuster A., Kilgus S., Bode-Lesniewska B., Ingold–Heppner B., Leong C., Storz M., Seifert B., Marino S., Schramm P.,Duumer R., Moch H.: Consistent expression of the stem cell renewalfactor BMI-1 in primary and metastatic melanoma. Int. J. Cancer,2007; 121: 1764-1770
  Google Scholar
• 28. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., MorrisomS.J.: Bmi-1 dependence distinguishes neural stem cell self–renewal from progenitur proliferation. Nature, 2003; 425: 962-967
  Google Scholar
• 29. Nowak K., Kerl K., Fehr D., Kramps C., Gessner C., Killmer K.,Samans B., Berwanger B., Christiansen H., Lutz W.: BMI-1 is a targetgene of E2F-1 and is strongly expressed in primary neuroblastomas.Nucleic Acids Res., 2006; 34: 1745-1754
  Google Scholar
• 30. Raaphorst F.M.: Self-renewal of hematopoetic and leukemic stemcells: a central role for the Polycomb-group gene Bmi-1. Trends Immunol.,2003; 24: 522-524
  Google Scholar
• 31. Raaphorst F.M., Otte A.P., van Kemenade F.J., Blokzijl T., Fieret E.,Hamer K.M., Satijn D.P., Meijer C.J.: Distinct BMI-1 and EZH2 expressionpatterns in thymocytes and mature T cells suggest a role forPolycomb genes in human T cell differentiation. Trends Immunol.,2001; 166: 5925-5934
  Google Scholar
• 32. Riley R.D., Heney D., Jones D.R., Syrton A.J., Lambert P.C., AbramsK.R., Young B., Wailoo A.J., Burchill S.A.: A systematic review of molecularand biological tumor markers in neuroblastoma. Clin. CancerRes., 2004; 10: 4-12
  Google Scholar
• 33. Rudolph P., Lappe T., Hero B., Brrthold F, Parwaresch R., HarasD., Schmidt D.: Prognostic significance of the proliferative activityin neuroblastoma. Am. J. Pathol., 1997; 150: 133-145
  Google Scholar
• 34. Schleiermacher G., Janoueix-Lerosey I., Ribeiro A., KlijanienkoJ., Couturier J., Pierron G., Mosseri V., Valent A., Auger N., PlantazD., Rubie H., Valteau-Couanet D., Bourdeaut F., Combaret V., BergeronC., Michon J., Delattre O.: Accumulation of segmental alterationsdetermines progression in neuroblastoma. J. Clin. Oncol.,2010; 28: 3122-3130
  Google Scholar
• 35. Schmidt M.L., Lal A., Seeger R.C., et al.: Favorable prognosis forpatients 12 to 18 months of age with stage 4 nonamplified MYCNneuroblastoma: a Children’s Cancer Group study. J. Clin. Oncol., 2005;23: 6474-6480
  Google Scholar
• 36. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., RoaldB., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., CastlerberryR.P.: The International Neuroblastoma Pathology Classification (theShimada system). Cancer, 1999; 86: 364-372
  Google Scholar
• 37. Simon J.A.: Policomb group proteins. Curr. Biol., 2003; 13: 79-80
  Google Scholar
• 38. Song L., Zeng M., Liao W., Hang L., Mo H., Liu W., Shao Y., WuQ., Li M., Fu Y., Huang W., Goberdhan P.D., Band V., Zeng Y.: Bmi-1 isa novel molecular marker of nasopharyngeal carcinoma progressionand immortalizes primary human nasopharyngeal epithelial cells.Cancer Res., 2006; 66: 6225-6232
  Google Scholar
• 39. Tabata T.: Genetics of morfogen gradients. Net. Rev. Genet.,2001; 2: 620-630
  Google Scholar
• 40. Taran K., Kobos J., Sitkiewicz A., Sporny S.: Estimation of prognosticvalue of CD44 expression in neuroblastic tumors in children.Folia Neuropathol., 2007; 45: 126-132
  Google Scholar
• 41. Taran K., Kobos J., Sporny S.: Estimation of diagnostic value ofchosen markers of neural differentiation in neuroblastoma group oftumors and pPNETs. Pol. J. Pathol., 2008, 59, 195-199
  Google Scholar
• 42. Taran K., Owecka A., Kobos J.: Prognostic importance of CyclinE1 expression in neuroblastic tumors in children. Pol. J. Pathol.,
  Google Scholar
• 43. Tweedle D.A., Malcolm A.J., Brown N., Pearson A.D., Lunnec J.:Evidence for the development of p53 mutations after cytotoxic therapyin neuroblastoma cell line. Cancer Res., 2001; 61: 8-13
  Google Scholar
• 44. Tweddle D.A., Malcolm A.J., Cole M., Pearson A.D.J., Lunet J.:p53 cellular localization and function in neuroblastoma: evidencefor defective G1 arrest despite WAF1 induction in MYCN amplifiedcells. Am. J. Patol., 2001; 158: 2067-2077
  Google Scholar
• 45. Tweddle D.A., Person A.D.J., Haber M., Morris M.D., Xue C., FlemingC., Lunet J.: The p53 pathway and its inactivation in neuroblastoma.Cancer Lett., 2003; 197: 93-98
  Google Scholar
• 46. Uccini S., Colarossi C., Scarpino S., Boldrini R., Natali P.G., NicotraM.R., Perla F.M., Mannarino O., Altavista P., Boglino C., CappelliC.A., Cozzi D., Donfrancesco A., Kokai G., Losty P.D., McDowell H.P.,Dominici C.: Morphological and molecular assessment of apoptoticmechanisms in peripheral neuroblastic tumors. Br. J. Cancer,2006; 95: 49-55
  Google Scholar
• 47. Vermeulen J., De Preter K., Mestdagh P., Laureys G., SpelemanF., Vandesompele J.: Modak S, Nai-Kong V.: Neuroblastoma: therapeuticstrategies for a clinical enigma. Cheung Cancer TreatmentReviews, 2010; 36: 307-317
  Google Scholar
• 48. Vogan K., Bernstein M., Leclerc J.M., Brisson L., Brossard J.,Brodeur G.M., Pelletier J., Gros P.: Absence of p53 gene mutation inprimary neuroblastoma. Cancer Res., 1993; 53: 5269-5273
  Google Scholar
• 49. Wang H., Pan K., Zhang H.K., Weng D.S., Zhou J., Li J.J., Huang W.,Song H.F., Chen M.S., Xia J.C.: Increased polycomb-group oncogeneBmi-1 exression correlated with poor prognosis in hepatocellularcarcinoma. J. Cancer Clin. Oncol., 2008; 134: 535-541
  Google Scholar

Pełna treść artykułu